Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Pharmaceutical Preparations · Dublin,
Our rating: Positive
Positive reaffirmed at $229.74, moderate conviction, November 3, 2026.
Breaks if: The Positive call rests on two premises: durable free cash flow and a franchise that continues to grow. It is invalidated if trailing-twelve-month free cash flow falls below $900M at any point through mid-2027 — roughly a 30% decline from the reported $1.3B — signaling the cash engine is genuinely impaired rather than the net loss being an amortization artifact. Separately, a year-on-year revenue decline in two consecutive quarterly prints through that same window would break the modest-growth premise on which the valuation case rests and would call for a move to Cautious.
Key figures
| Market value | $14.8B |
|---|---|
| Revenue, last 12 months | $4.7B |
| Net income, last 12 months | $206M |
| Free cash flow, last 12 months | $1.6B |
| Price to earnings | 71.8× |
| Free cash flow yield | 11.0% |
| Dividend yield | 0.0% |
| Operating margin | 9.0% |
| Return on equity | 5.1% |
| Beta to the S&P 500 | 0.70 |
| Volatility, annualized | 34.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $1.2B | 10.4% | $-7.48 | $490M |
| June 30, 2026 | $1.2B | 15.5% | $2.78 | $398M |
| March 31, 2026 | $1.1B | 19.1% | $4.43 | $389M |
| December 31, 2025 | $1.2B | 10.1% | $3.34 | $346M |
| September 30, 2025 | $1.1B | 6.7% | $4.08 | $460M |
| June 30, 2025 | $1.0B | 2.1% | $-11.74 | $76M |
| March 31, 2025 | $898M | −0.5% | $-1.52 | $416M |
| December 31, 2024 | $1.1B | 7.5% | $3.02 | $385M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $1.36B: Claude 52%, Gemini 75%, Mistral 48%
- Diluted earnings per share are at least $3.34: Claude 35%, Gemini 35%, Mistral 50%
- Free cash flow for the quarter is at least $0.35B: Claude 60%, Gemini 90%, Mistral 82%
11 ledger entries and 43 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.